Literature DB >> 24634527

Management of severe dabigatran-related hemorrhage: case report, considerations for management, and recommendations.

Ian Plener1, Sharon Sadry1, Lee Mozessohn2, Justin Y Lee3, Damen Man4, Nadine Shehata5, Jeffrey M Singh6.   

Abstract

Entities:  

Year:  2014        PMID： 24634527      PMCID： PMC3952908          DOI： 10.4212/cjhp.v67i1.1322

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  16 in total

Review 1.  How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.

Authors:  Sam Schulman; Mark A Crowther
Journal:  Blood       Date:  2012-02-01       Impact factor: 22.113

2.  Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.

Authors:  Theodore E Warkentin; Peter Margetts; Stuart J Connolly; Andre Lamy; Chris Ricci; John W Eikelboom
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  Bleeding risk with dabigatran in the frail elderly.

Authors:  Paul Harper; Laura Young; Eileen Merriman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 4.  Dabigatran etexilate: a new oral thrombin inhibitor.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  Circulation       Date:  2011-04-05       Impact factor: 29.690

Review 5.  Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Authors:  Scott Kaatz; Peter A Kouides; David A Garcia; Alex C Spyropolous; Mark Crowther; Jim D Douketis; Anthony K C Chan; Andra James; Stephan Moll; Thomas L Ortel; Elizabeth M Van Cott; Jack Ansell
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

6.  Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.

Authors:  Ennie L Cano; Marta A Miyares
Journal:  Am J Geriatr Pharmacother       Date:  2012-03-03

Review 7.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

8.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

9.  Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Authors:  Wei Zhou; Sönke Schwarting; Sergio Illanes; Arthur Liesz; Moritz Middelhoff; Markus Zorn; Martin Bendszus; Sabine Heiland; Joanne van Ryn; Roland Veltkamp
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

10.  Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Authors:  Joachim Stangier; Hildegard Stähle; Karin Rathgen; Reinhold Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.